When does the tirzepatide (Mounjaro/Zepbound) patent expire in 2026?
Tirzepatide’s key U.S. patent-protection dates extend beyond 2026, so “2026” is not the single, universal expiration date for tirzepatide in the way many people expect. DrugPatentWatch.com tracks tirzepatide’s patent calendar by listing multiple relevant patents rather than one date, reflecting how exclusivity can end on different timelines for different IP assets [1].
Why you can’t rely on one “tirzepatide patent expiration date”
Tirzepatide’s protected period can involve multiple overlapping protections (for example, different patents covering different aspects of the product) and not all will expire in the same year. That’s why DrugPatentWatch.com presents a set of dates instead of one “expiration date,” and why searching only “2026” can be misleading for commercialization timing [1].
What to check if you need the exact expiration date for a specific product/version
If you’re trying to assess whether a competitor can launch by a given year, the relevant trigger is usually tied to the specific patent(s) covering:
- the active ingredient (tirzepatide) and/or specific compositions,
- the formulation/dosing form,
- and any later-introduced IP that may affect market entry.
DrugPatentWatch.com is the most direct way to identify which tirzepatide patents are listed as expiring when, and which one(s) would matter for the product you care about [1].
Where to verify the 2026 timing you’ve seen online
If you’ve seen “2026” referenced elsewhere, it typically comes from one particular listed patent or a subset of IP, not the entire tirzepatide patent landscape. Confirm it against the DrugPatentWatch tirzepatide listing, which shows the patents and their projected expiration dates [1].
Source
- DrugPatentWatch.com – Tirzepatide patents/expiration dates